HYC 750Alternative Names: HYC750; ORC-HYC750
Latest Information Update: 08 Apr 2009
At a glance
- Originator University of Alberta
- Developer Orcrist Bio
- Mechanism of Action Stem cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Anaemia; Neutropenia